Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Michelle Chambers

Dermatology Columbus, OH Medical Doctor

NPI 1538152954 CMS profile 342307

1830 Bethel Road, Suite C, Columbus, OH 43220

Open in the dashboard

General payments

$3,974

250 records reported · program years 2019–2024

Research payments

$7,206

Paid to them · 4 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,883,035 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Michelle Chambers of Columbus, OH is reported in the CMS Open Payments database as having received $3,974 across 250 general payments and $7,206 in research payments paid to them. Separately, studies naming them as principal investigator received $1,883,035 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 81st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $2,631 1
2022 General $56 3
2021 General $1,158 78
2021 Research $3,875 2
2020 General $1,242 77
2020 Research $700 1
2019 General $1,518 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Chambers
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Michelle Chambers were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Michelle Chambers Dermatology median Middle half National median
2019 $1,518 $454 $129–$1,240 $163
2020 $1,242 $235 $81–$756 $114
2021 $1,158 $377 $108–$1,108 $132
2022 $56 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $860 58 payments
  2. Genzyme Corporation $333 12 payments
  3. Novartis Pharmaceuticals Corporation $317 23 payments
  4. Amgen Inc. $308 27 payments
  5. Lilly USA, LLC $271 16 payments
  6. Galderma Laboratories, L.P. $235 15 payments
  7. Pfizer Inc. $209 16 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $190 14 payments
  9. Celgene Corporation $187 6 payments
  10. Regeneron Healthcare Solutions, Inc. $156 10 payments
  11. Other $910 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,902 249 payments
  2. Education $72 1 payment
Products named General payments · program years 2019–2024
  1. HUMIRA $728 47 payments
  2. SKYRIZI $402 33 payments
  3. DUPIXENT Immunology $397 12 payments
  4. Otezla Inflammation $293 26 payments
  5. TALTZ $271 16 payments
  6. EUCRISA $209 16 payments
  7. Otezla Dermatology $187 6 payments
  8. COSENTYX $155 8 payments
  9. TargaDox $140 10 payments
  10. DUPIXENT Inflammation And Immunology $128 8 payments
  11. Other $1,708 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $7,206 4 payments

Records

254 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record